Reverse DCF
What growth does the market imply for INDRAMEDCO?
Working backwards from the current price to find the FCF growth assumption baked in.
reasonable
10.4% implied annual FCF growth
The market's growth assumption looks achievable — it is in line with or below what this company has historically delivered.
Current Price
₹406
Historical Growth
11.1%
FCF Yield
3.23%
Price / FCF
30.9x
Plain English
To justify today's price of $406.45, INDRAMEDCO.NS needs to grow its free cash flow at 10.4% per year for the next 10 years. That is 0.6% slower than its historical growth rate of 11.1%. This looks achievable — the market is not pricing in heroic assumptions. There may be genuine upside if the company executes.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Half implied | 5.2% | ₹270 | -33.5% |
| GDP rate | 10.0% | ₹395 | -2.8% |
| Implied | 10.4% | ₹409 | +0.6% |
| Historical | 11.1% | ₹430 | +5.9% |
At Historical Growth Rate
It would take 9 years for INDRAMEDCO to organically grow into today's price assuming its historical FCF growth of 11.1%.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.